Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2016, Article ID 7157039, 5 pages
http://dx.doi.org/10.1155/2016/7157039
Research Article

Expressions of Endocan in Patients with Meningiomas and Gliomas

1Department of Biochemistry, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
2Department of Neurosurgery, Samatya Training and Research Hospital, Istanbul, Turkey
3Department of Neurosurgery, Cerrahpasa Medical Faculty, Istanbul University, Fatih, 34098 Istanbul, Turkey
4Department of Forensic Medicine, Uludag University, Bursa, Turkey

Received 20 April 2016; Revised 21 June 2016; Accepted 30 June 2016

Academic Editor: Lance A. Liotta

Copyright © 2016 Pinar Atukeren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. Endocan has been shown to be a marker for several cancers and may show degree of malignancy. The aim of this study is to assess tissue levels of endocan in common brain tumors, namely, meningiomas, low-grade gliomas (LGGs), and high-grade gliomas (HGGs). Patients and Methods. Endocan was assayed by commercially available enzyme linked immunosorbent assay (ELISA) kits in a total of 50 brain tumors (20 meningiomas, 19 LGGs, and 20 HGGs) and 15 controls. The results were compared to control brain tissues. Results. Each tumor group showed significant higher levels of endocan compared to controls (). In addition, endocan levels showed steady increase from the least (meningiomas) to the most (HGGs) malignant tumors and positive correlation was noted between the degree of malignancy and endocan level (). Conclusion. Endocan, a vital molecule for angiogenesis, is expressed in common brain tumors and results suggest that endocan could be a marker for malignancy.